ArticleBMC health services research2022
Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Article in BMC health services research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.Blood advances · 2023Trial
- "Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?"Future science OA · 2026Article
- Analgesic Utilization Pattern and Cost of Managing Children with Sickle Cell Diseases: a Retrospective Single-site Audit.Journal of racial and ethnic health disparities · 2026Article
- Hydroxyurea Therapy in Sickle Cell Disease: Evaluating Healthcare Costs and Utilization in a Brazilian Tertiary Setting.Blood global hematology · 2025Article
- Economic burden of sickle cell disease in Australia.Internal medicine journal · 2025Article
- Determinants of knowledge, attitudes, and practice towards sickle cell disease in Alebtong district, Lango region, Northern Uganda.BMC public health · 2025Article
- Emergency Department Utilization by Pediatric Patients With Sickle Cell Disease in Basrah, Iraq.Cureus · 2024Article
- Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease.Annals of hematology · 2023Article
- Analysis of the costs of the basic care line for sickle cell disease in Brazilian children under 5 years of age.Hematology, transfusion and cell therapy · 2023Article
- Economic burden of sickle cell disease in Brazil.PloS one · 2022Article
- Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe costs associated with the treatment of sickle cell disease (SCD) are understudied in low and middle-income countries (LMIC). We evaluated the cost of treating SCD-related acute complications and the potential cost-savings of hydroxyurea in a specialized hematology center in Brazil.
methodsThe costs (US dollars) of emergency department (ED) and hospitalizations from SCD-related complications between 01.01.2018 and 06.30.2018 were ascertained using absorption and micro-costing approaches. The reasons for acute hospital visits were grouped as: 1) vaso-occlusive (VOC) pain, 2) infection, 3) anemia exacerbation, and 4) chronic organ damage complications. Hydroxyurea adherence was estimated by medication possession ratio (MPR) during the study period.
resultsIn total, 1144 patients, median age 17 years (range 0-70), 903 (78.9%) with HbSS/HbSβ DISCUSSION: In a LMIC hematology-specialized center, VOCs accounted for most acute visits from patients with SCD, but costs were highest due to anemia exacerbation. Analgesics, antibiotics, and housing drove most expenses. Hydroxyurea may reduce ED costs among individuals with HbSS/HbSβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.